Prognostic significance of systemic immune inflammation indices and prognostic nutritional index before CDK4/6 inhibitor therapy in hormone receptor positive, HER2 negative metastatic breast cancer patients

Authors : Burçin ÇAKAN DEMİREL, Arzu YAREN, Atike Gökçen DEMİRAY, Burcu YAPAR TAŞKÖYLÜ, Tolga DOĞAN, Melek ÖZDEMİR, Taliha GÜÇLÜ KANTAR, Canan KARAN, Serkan DEĞİRMENCİOĞLU, Gamze GOKOZ DOGU

Pages : 682-695

Doi:10.31362/patd.1268419

View : 42 | Download : 52

Publication Date : 2023-10-01

Article Type : Research Paper

Abstract :Purpose: As systemic inflammatory indices and prognostic nutritional index are associated with poor prognosis in many tumor types, the goal of the present study was to ascertain their effect along with the neutrophil/lymphocyte ratio, platelet/lymphocyte ratio, lymphocyte/monocyte ratio, C-reactive protein/albumin ratio, and systemic inflammatory response index on the progression-free survival insert ignore into journalissuearticles values(PFS); and overall survival insert ignore into journalissuearticles values(OS); of hormone receptor-positive HER2-negative insert ignore into journalissuearticles values(HR+/HER2−); metastatic breast cancer patients before CDK4/6 inhibitor treatment. Materials and methods: The medical records of 79 patients with HR+/HER2− metastatic breast cancer who presented at the Medical Oncology Outpatient Clinic between January 2018 and May 2022 were retrospectively analyzed to gather relevant data measured before CDK4/6 inhibitor treatment in order to establish the effect of key markers on their PFS and OS. Results: The median age of the participating patients, 70 insert ignore into journalissuearticles values(88.6%); of whom were postmenopausal, was 53 years insert ignore into journalissuearticles values(range 26-80 years);. While 68 patients insert ignore into journalissuearticles values(86.1%); had a 0 performance score, 10 insert ignore into journalissuearticles values(12.7%); developed metastases during adjuvant endocrine therapy. Factors affecting PFS were age <50 insert ignore into journalissuearticles values(p=0.061);, metastasis development during adjuvant endocrine therapy insert ignore into journalissuearticles values(p=0.09); and C-reactive protein/albumin ratio insert ignore into journalissuearticles values(p=0.019);, while OS was primarily influenced by age <50 insert ignore into journalissuearticles values(p=0.069); and metastasis development during adjuvant endocrine therapy insert ignore into journalissuearticles values(p=0.012);. Conclusion: In the examined HR+/HER2− metastatic breast cancer patients, systemic inflammatory indices and prognostic nutritional index before CDK4/6 inhibitor treatment affected PFS. In addition, metastasis development during adjuvant endocrine therapy, progesterone receptor percentage, and age below 50 years emerged as prognostic factors for shorter overall survival.
Keywords : HR Her2 meme kanseri, CDK4 6 inhibitörü, sistemik inflamatuar indeksler, prognostik nutrisyonel indeks, PSK